Stock GILD GILEAD SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Gilead Sciences, Inc.

Equities

GILD

US3755581036

Real-time Estimate Cboe BZX
Other stock markets
 12:02:01 2024-06-10 pm EDT 		5-day change 1st Jan Change
64.46 USD -0.37% Intraday chart for Gilead Sciences, Inc. +1.12% -20.82%
05:16pm Arcus Completes Enrollment in Phase 3 Trial of Domvanalimab-Containing Regimen for Stomach Cancer MT
Jun. 06 Gilead Says Bulevirtide With PegIFN Data 'Superior' to Bulevirtide Monotherapy; Achieves 46% Rate of Undetectable HDV RNA MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Arcus Completes Enrollment in Phase 3 Trial of Domvanalimab-Containing Regimen for Stomach Cancer
MT
Combination therapy may hold potential for severe viral hepatitis
AQ
Gilead's Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis
AQ
Gilead Says Bulevirtide With PegIFN Data 'Superior' to Bulevirtide Monotherapy; Achieves 46% Rate of Undetectable HDV RNA
MT
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA
BU
Gilead Sciences, Inc. Announces Data from the Phase 2b MYR204 Open-Label Study
CI
Transcript : Gilead Sciences, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 11:00 AM
Johnson & Johnson Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Pediatric Indication for HIV-1 Therapy PREZCOBIX
AQ
Gilead Sciences Says Investigational Chronic Liver Disease Drug Shows 'Sustained Efficacy' in Long-Term Trial
MT
Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis
BU
Gilead Sciences, Inc. Announces Two-Year Interim Results from the Ongoing Assure Study of Investigational Seladelpar for the Treatment of Primary Biliary Cholangitis, A Rare, Chronic Inflammatory Liver Disease
CI
Sector Update: Health Care Stocks Rise Late Afternoon
MT
Sector Update: Health Care Stocks Rise Tuesday Afternoon
MT
Gilead Sciences Agrees to $40 Million Settlement of Federal TDF Lawsuit
MT
Gilead Sciences : Statement on Agreement in Principle to Resolve Federal TDF Litigation
PU
Gilead Sciences Unit Says Tecartus Improves Overall Survival in Leukemia, Yescarta Well-Tolerated in Lymphoma
MT
Kite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
BU
Kite?S Tecartus® Demonstrates Sustained Overall Survival in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
CI
Encouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma
BU
Kite Announces Data from A Pilot Study in Collaboration with Dana-Farber Cancer Institute
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GILD Stock
  4. News Gilead Sciences, Inc.